DRAVP_ID	Name	Sequence	Target_Organism	Pubchem	Molecular_Formula	DrugBank_Accession_Number	NCI_Thesaurus_Code	UNII	CAS_Number	Chembl	Pubmed_ID	Comment	Description	Chemical_structure_depiction	Condition_Disease	Type	Group	Connectives
DRAVPc042	Meplazumab	Not Available	SARS-CoV-2	405560467	Not Available	DB16465	Not Available	0EL07E29VQ	Not Available	Not Available	32307653##32291112	No comments found.	"Meplazumab is an anti-CD147 antibody, which is a recepor on host cells for viruses such as SARS-CoV2. Meplazumab's inhibition of CD147 binding to the spike proteins of viruses is thought to inhibit their entry.It is investigated as an add-on therapy in patients with COVID-19 pneumonia."	Structure not available	COVID-19	Antibody	Investigational	Anti-SARS-CoV-2
DRAVPc043	Regdanvimab	">Regdanvimab light chain:
ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
>Regdanvimab heavy chain:
QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"	SARS-CoV-2	434321767	Not Available	DB16405	Not Available	I0BGE6P6I6	2444308-95-4	CHEMBL4650462	33319649##33436577	No comments found.	"Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Regdanvimab is indicated in the EU for the treatment of adult patients with COVID-19 who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19."	Structure not available	COVID-19	Antibody	Phase ｊclinical trial	Anti-SARS-CoV-2
DRAVPc040	Zansecimab	"Subunit 1
QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
Subunit 2
QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
Subunit 3
DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	SARS-CoV-2	434370480	Not Available	DB16389	Not Available	A67ZN01CAW	2415205-37-5	CHEMBL4650486	30701027	No comments found.	"Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19). It is a humanized IgG4 isotype antibody that neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. The mechanism behind the neutralization is due to the antibody binding with high affinity to, and inhibiting Ang2."	Structure not available	COVID-19	Antibody	Phase ｊclinical trial	Anti-SARS-CoV-2
DRAVPc041	Avdoralimab	"Subunit 1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
Subunit 2
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
Subunit 3
EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	SARS-CoV-2	402425685	Not Available	DB16392	Not Available	DW4CE8MKS9	2226393-85-5	CHEMBL4594463	Not Available	No comments found.	Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).	Structure not available	COVID-19	Antibody	Phase ｊclinical trial	Anti-SARS-CoV-2
DRAVPc039	Astegolimab	"Subunit 1
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 2
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 3
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	SARS-CoV-2	402425721	Not Available	DB16386	Not Available	27TW751DTH	2173054-79-8	CHEMBL4594385	Not Available	No comments found.	Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).	Structure not available	COVID-19	Antibody	Phase ｊclinical trial	Anti-SARS-CoV-2
DRAVPc037	Gontivimab(ALX0171)	"Subunit 1
DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS"	RSV	402425649	Not Available	DB16179	Not Available	DY8W536BUY	1257358-38-5	CHEMBL4297692	Not Available	No comments found.	Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).	Structure not available	Respiratory Syncytial Virus Lower Respiratory Tract Infection	Antibody	Phase ｊclinical trial	Anti-RSV
DRAVPc038	Ansuvimab	"Subunit 1
EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 2
EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 3
DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	EBOV	433770931	Not Available	DB16385	Not Available	TG8IQ19NG2	2375952-29-5	CHEMBL4594388	31909070##26917592##26917593	No comments found.	"Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit EBOV outbreak 11 years after infection, which displays strong glycan-independent binding to a conserved region of the GP1,2 protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD."	Structure not available	Zaire ebolavirus infection	Antibody	"Approved, Investigational"	Anti-EBOV
DRAVPc036	Gimsilumab(MORAB-022)	"Subunit 1
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVHEALHNHYTQKSLSLSPGK
Subunit 2
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVHEALHNHYTQKSLSLSPGK
Subunit 3
EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	SARS-CoV-2	381127889	Not Available	DB15280	Not Available	8961SFA7R3	1648796-29-5	CHEMBL2109430	Not Available	No comments found.	Gimsilumab is under investigation in clinical trial and used for COVID-19.	Structure not available	COVID-19	Antibody	Phase ｊclinical trial	Anti-SARS-CoV-2
DRAVPc035	Ibalizumab	"Subunit 1
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
Subunit 2
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
Subunit 3
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	HIV	347911363	Not Available	DB12698	Not Available	LT369U66CE	680188-33-4	CHEMBL1743029	14722894##15180541	No comments found.	"Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes.This drug was approved in March 2018 for the management of treatment-resistant HIV, in October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration."	Structure not available	HIV infection	Antibody	Approved	Anti-HIV
DRAVPc034	Leronlimab(PRO 140)	Not Available	"HIV,SARS-CoV-2"	135308456	Not Available	DB05941	Not Available	Y1J4NP8FF0	674782-26-4	CHEMBL2109343	20377413##11134270	No comments found.	"Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.4 It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients."	Structure not available	"HIV infection, COVID-19"	Antibody	Phase ｋ clinical trial	"Anti-HIV,Anti-SARS-CoV-2"
DRAVPc033	Ansuvimab	"Subunit 1
EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 2
EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Subunit 3
DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Subunit 4
DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	EBOV	433770931	Not Available	DB16385	Not Available	TG8IQ19NG2	2375952-29-5	CHEMBL4594388	31909070##31774950##30686586	No comments found.	"Ansuvimab is a fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD."	Structure not available	Zaire ebolavirus infection	Antibody	Approved	Anti-EBOV
DRAVPc031	Maftivimab(REGN-3479)	Not Available	EBOV	381609201	C6368H9886N1706O2008S46	DB15899	Not Available	KOP95331M4	2135632-36-7	CHEMBL4298184	32080199##30333617##29860496	No comments found.	"Maftivimab is part of a product containing three monoclonal IgG1百 antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.Maftivimab is indicated in combination with Odesivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB?, formerly referred to as REGN-EB3, combines the three humanized IgG1百 mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB? is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020."	Structure not available	Zaire ebolavirus infection	Antibody	Approved	Anti-EBOV
DRAVPc032	Odesivimab(REGN-3471)	Not Available	EBOV	381608746	C6506H10024N1720O2030S42	DB15900	Not Available	UY9LQ8P6HW	2135632-30-1	CHEMBL4298188	32080199##30333617##29860496	No comments found.	"Odesivimab is part of a product containing three monoclonal IgG1百 antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Odesivimab is indicated in combination with Maftivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB?, formerly referred to as REGN-EB3, combines the three humanized IgG1百 mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB? is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020."	Structure not available	Zaire ebolavirus infection	Antibody	Approved	Anti-EBOV
DRAVPc030	Atoltivimab(REGN-3470)	Not Available	EBOV	381609025	C6448H9954N1726O2002S44	DB15898	Not Available	FJZ07Q63VY	2135632-29-8	CHEMBL4298183	32080199##30333617##29860496	No comments found.	"Atoltivimab is part of a product containing three monoclonal IgG1百 antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Atoltivimab is indicated in combination with Odesivimab and Maftivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection.  INMAZEB?, formerly referred to as REGN-EB3, combines the three humanized IgG1百 mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB? is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020."	Structure not available	Zaire ebolavirus infection	Antibody	Approved	Anti-EBOV
DRAVPc029	"Bamlanivimab(LY-3819253,LY-CoV555)"	Not Available	SARS-CoV-2	434370493	C6498H10068N1732O2032S46	DB15718	Not Available	45I6OFJ8QH	2423943-37-5	CHEMBL4650379	33024963##33113295	No comments found.	"Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. Bamlanivimab is a neutralizing IgG1百 mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells. Under the EUA granted in February 2021, bamlanivimab is used in combination with etesevimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19.The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children."	Structure not available	COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc028	Tixagevimab	Not Available	SARS-CoV-2	434370464	C6488H10034N1746O2038S50	DB16394	Not Available	F0LZ415Z3B	2420564-02-7	Not Available	32651581##34548634	No comments found.	"Tixagevimab is an extended half-life recombinant monoclonal IgG1百 antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. It is not approved for any indication by the FDA. Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. "	Structure not available	COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc027	Cilgavimab(AZD1061)	Not Available	SARS-CoV-2	440964522	C6626H10218N1750O2078S44	DB16393	Not Available	1KUR4BN70F	2420563-99-9	Not Available	32651581##34548634	No comments found.	"Cilgavimab is an extended half-life recombinant monoclonal IgG1百 antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Cilgavimab is not approved for any indication by the FDA. Cilgavimab, in combination with tixagevimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,5 and was approved in Canada soon after, on April 14, 2022."	Structure not available	COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc025	Human interferon beta	EEIKQLQQFQKED		101632004	C72H115N19O26	DB14999	Not Available	V9GU1EM8SF	74899-71-1	CHEMBL2108510	Not Available	No comments found.	"Human interferon beta is a polypeptide drug which could used in the treatment of COVID-19. Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS). It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity."	DRAVPc025.png	COVID-19	Protein	Approved	
DRAVPc026	Palivizumab	VH region:  QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS	RSV	46506637	Not Available	DB00110	Not Available	DQ448MW7KS	188039-54-5	CHEMBL1201586	Not Available	No comments found.	"Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. It is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients."		Severe Respiratory Syncytial Virus Infection	Antibody	Approved	Anti-RSV
DRAVPc023	Aldesleukin	MPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT	HIV	46508054	C690H1115N177O202S6	DB00041	Not Available	M89N0Q7EQR	110942-02-4	CHEMBL1201438	Not Available	No comments found.	"Aldesleukin is a recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells."	DRAVPc023.png	"HIV infection, COVID-19"	Protein	Approved	Anti-HIV
DRAVPc024	Bulevirtide	TNLSVPNPLGFFPDPAFGANSNNPDWDFNPNKDHWPEANKVG	"HBV,HDV"	381128209	Not Available	DB15248	Not Available	WKM56H3TLB	2012558-47-1	CHEMBL4297711	22161394##32926353	No comments found.	"The N-terminal of Bulevirtide is tetradecanoylglycyl and C-terminal is amide. Bulevirtide is a drug for the treatment of chronic Hepatitis D infection in adults with compensated liver disease.Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency."		Chronic Hepatitis D infection	Peptide	Approved(HDV)	Anti-HBV
DRAVPc055	Nelfinavir	Not Available	HIV	64143	C32H45N3O4S	DB00220	C29285	HO3OGH5D7I	159989-64-7	CHEMBL584	9397180##36466430##33372574	No comments found.	"Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles."		HIV Infection	Synthetic peptide	Approved	Anti-HIV
DRAVPc022	Albinterferon Alfa-2B	Not Available	HCV	347910117	C3796H5937N1015O1143S50	DB05396	Not Available	4DVS4AG4DF	472960-22-8	CHEMBL2107842	12388634	No comments found.	"Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-汐-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug."		"Chronic HCV infection, Chronic HBV infection"	Protein	Phase ｋ clinical trial	Anti-HCV
DRAVPc021	Interferon alfacon-1	MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE	HCV	46505985	C860H1353N227O255S9	DB00069	Not Available	56588OP40D	118390-30-0	CHEMBL1201557	8836913	No comments found.	Interferon alfacon-1 is a recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.	Structure not available	Chronic HCV infection	Protein	Approved	Anti-HCV
DRAVPc056	Remdesivir	Not Available		121304016	C27H35N6O8P	DB14761	C152185	3QKI37EEHE	1809249-37-3	CHEMBL4065616	32350436##35000553##36466430	No comments found.	"Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families.Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials."		COVID-19	Peptide like Small molecule	Approved	Anti-SARS-CoV-2
DRAVPc020	Interferon beta-1b	SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN	"SARS-CoV-2,HIV"	46504458	C908H1408N246O253S6	DB00068	Not Available	TTD90R31WZ	145155-23-3	CHEMBL1201563	9890522	No comments found.	Interferon beta-1b is a form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.		"HIV infection, COVID-19"	Protein	Approved	"Anti-SARS-CoV-2,Anti-HIV"
DRAVPc019	Interferon beta-1a	MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN	SARS-CoV-2	46504899	C908H1408N246O252S7	DB00060	Not Available	XRO4566Q4R	145258-61-3	CHEMBL1201562	Not Available	No comments found.	Interferon beta-1a is a form of recombinant human interferon which could used for the treatment of COVID-19.		COVID-19	Protein	Approved	Anti-SARS-CoV-2
DRAVPc018	Interferon gamma-1b	CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ	"HCV,HIV"	46507194	C761H1206N214O225S6	DB00033	Not Available	21K6M2I7AG	98059-61-1	CHEMBL1201564	16375755##14525967	No comments found.	Interferon gamma-1b is a form of recombinant human interferon used to treat infections associated with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV).		"Chronic HCV infection, HIV infection"	Protein	Approved	"Anti-HCV,Anti-HIV"
DRAVPc017	Peginterferon alfa-2b	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	"HCV,HBV"	46506669	Not Available	DB00022	Not Available	G8RGG88B68	215647-85-1	CHEMBL1201561	28497432##25585348	No comments found.	"Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).It is approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs."	DRAVPc017.png	Chronic HCV infection	Protein	Approved	"Anti-HCV,Anti-HBV"
DRAVPc015	Interferon alfa-n1	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	HIV	46506227	C860H1353N227O255S9	DB00011	Not Available	41697D4Z5C	74899-72-2	CHEMBL2108509	Not Available	No comments found.	"Interferon alfa-n1 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. It consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes."	Structure not available	HIV infection	Protein	Phase ｊclinical trial	Anti-HIV
DRAVPc016	Interferon alfa-n3	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE		46508902	Not Available	DB00018	Not Available	47BPR3V3MP	Not Available	CHEMBL2109047	10868311	No comments found.	"Interferon alfa-n3 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD)."	Structure not available	"HIV infections, SARS infection"	Protein	Approved	
DRAVPc057	Glecaprevir	Not Available		66828839	C38H46F4N6O9S	DB13879	C170029	K6BUU8J72P	1365970-03-1	CHEMBL3545363	24282816##36466430	No comments found.	"Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both. "		Chronic HCV infection	Peptide like Small molecule	Approved	Anti-HCV
DRAVPc013	Atazanavir	Not Available	HIV	148192	C38H52N6O7	DB01072	C66872	QZU4H47A3S	198904-31-3	CHEMBL1163	32924827##19496633	No comments found.	"Atazanavir is an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety. Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003."	DRAVPc013.png	HIV infection	Peptidomimetic	Approved	Anti-HIV
DRAVPc058	Saquinavir	Not Available		441243	C38H50N6O5	DB01232	C29444	L3JE09KZ2F	127779-20-8	CHEMBL114	36466430	No comments found.	"Saquinavir is an aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. It is a member of quinolines and a L-asparagine derivative. Saquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the Treatment of human immunodeficiency virus-1(HIV-1)."		HIV infection	Peptidomimetic	Approved	Anti-HIV
DRAVPc014	Peginterferon alfa-2a	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	HCV	46504860	Not Available	DB00008	Not Available	Q46947FE7K	198153-51-4	CHEMBL1201560	28497432##25585348	No comments found.	"Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with Ribavirin or other antiviral drugs"	Structure not available	"Chronic HCV infection, Chronic HBV infection"	Protein	Approved	Anti-HCV
DRAVPc059	Indinavir	Not Available		5362440	C36H47N5O4	DB00224	C74585	9MG78X43ZT	150378-17-9	CHEMBL115	36466430	No comments found.	"Indinavir is a N-(2-hydroxyethyl)piperazine, a piperazinecarboxamide and a dicarboxylic acid diamide. It is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Indinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and mild elevations in indirect bilirubin concentration. Indinavir is a rare cause of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, antiretroviral therapy with indinavir may result in an exacerbation of the underlying chronic hepatitis B or C."		HIV infection.	Peptidomimetic	Approved	Anti-HIV
DRAVPc010	Golotimod	XW	HCV	6992140	C16H19N3O5	DB05475	C76497	637C487Y09	229305-39-9	CHEMBL2103812	34258744	X is a D-type glutamate with a gamma position on the side chain	"Golotimod(SCV-07) is a novel synthetic dipeptide containing the amino acids D-glutamine and L-tryptophan, which is used to treat hepatitis C by oral administration. SCV-07 has shown efficacy in treating various viral and bacterial infections."	DRAVPc010.png	Chronic HCV infection	Peptide	Phase ｊclinical trial	Anti-HCV
DRAVPc011	"Oglufanide(IM862, Glufanide)"	EW	HCV	100094	C16H19N3O5	DB05779	C76274	4RHY598T5U	38101-59-6	CHEMBL2111029	34258744	No comments found.	"Oglufanide is a synthetic dipeptide immunomodulator composed of L-glutamic acid and L-tryptophan joined by a peptide linkage and in development for the treatment of chronic hepatitis C viral infection. Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection."	DRAVPc011.png	Chronic HCV infection	Peptide	Phase ｊclinical trial	Anti-HCV
DRAVPc012	Telaprevir	Not Available	HCV	3010818	C36H53N7O6	DB05521	C81603	655M5O3W0U	402957-28-2	CHEMBL231813	22180548##28497432	No comments found.	"Telaprevir is an oligopeptide consisting of N-(pyrazin-2-ylcarbonyl)cyclohexylalanyl, 3-methylvalyl, octahydrocyclopenta[c]pyrrole-1-carboxy, and 3-amino-N-cyclopropyl-2-oxohexanamide residues joined in sequence. Telaprevir is an orally available peptidomimetic small molecule with activity against hepatitis C virus (HCV). Telaprivir is a selective protease inhibitor that targets the viral HCV NS3-4A serine protease and disrupts processing of viral proteins and formation of a viral replication complex."	DRAVPc012.png	Chronic HCV infection	Peptidomimetic	"Approved, Withdrawn"	Anti-HCV
DRAVPc060	Ritonavir	Not Available		392622	C37H48N6O5S2	DB00503	C1609	O3J8G9O825	155213-67-5	CHEMBL163	21501034##36466430	No comments found.	"Ritonavir is an L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. It is an antiretroviral protease inhibitor that is widely used in combination with other protease inhibitors in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Ritonavir is used in combination with other drugs to treat coronavirus disease 2019 (COVID-19) in patients who are at risk for progressing into a severe form of the disease."		HIV Infection	Peptidomimetic	Approved	Anti-HIV
DRAVPc009	Thymalfasin	SDAAVDTSSEITTKDLKEKKEVVEEAEN	"SARS-CoV-2,HBV"	16130571	C129H215N33O55	DB04900	C1253	W0B22ISQ1C	62304-98-7	CHEMBL2103979	15482167##35434596	No comments found.	"A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis.Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients."	DRAVPc009.png	"HBV infection, HCV infection"	Peptide	Approved	"Anti-SARS-CoV-2,Anti-HBV"
DRAVPc061	Sotrovimab	Not Available		472422617	Not Available	DB16355	C177059	1MTK0BPN8V	2423014-07-5	CHEMBL4650524	33907512##33319649	No comments found.	"Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy."		COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc008	Alisporivir(Debio-025)	XaVVLAaLLVX	"HCV,SARS-CoV-2"	11513676	C63H113N11O12	DB12139	C169774	VBP9099AA6	254435-95-5	CHEMBL1651956	32376613##21060866	The first X stands for D-Aminobutyric acid.The second X stands for Beta-methyl-tyrosine.	"Alisporivir is a non-immunosuppressive analogue of cyclosporine A and an inhibitor of cyclophilins, with potential antiviral activity. Upon oral administration, alisporivir targets and inhibits human host cyclophilins, thereby inhibiting hepatitis C virus (HCV) replication in hepatocytes. Alisporivir may also inhibit the replication of various coronaviruses. In addition, it may inhibit mitochondrial cyclophilin-D, which regulates mitochondrial permeability transition pore (mPTP) opening. This may prevent cell death and tissue damage. It has a role as an anticoronaviral agent."	DRAVPc008.png	"Chronic HCV infection, COVID-19"	Peptide	"Phase ｋ clinical trial(HCV infection treatment), Phase ｊ clinical trial(COVID-19)"	"Anti-HCV,Anti-SARS-CoV-2"
DRAVPc007	Albuvirtide	WEEMDREINNYTXLIHELIEESQNQQEKNEQELL	HIV	134694278	C204H306N54O72	Not Available	C179096	MG9PC54E43	1417179-66-8	CHEMBL4297257	32180205##34176425	X is a 3-maleimimidropropionic acid(MPA) modification.	"Albuvirtide (ABT) belongs to the class of HIV-1 fusion inhibitors. It is a 3-maleimimidopropionic acid (MPA)-modified peptide derived from the C-terminal heptad repeat sequence of HIV-1 gp41. It binds to gp41, blocking HIV-1 from entering and infecting certain cells"	DRAVPc007.png	HIV infection	Peptide	"Phase ｋ clinical trial(HCV infection treatment), Phase ｊ clinical trial(COVID-20)"	Anti-HIV
DRAVPc006	Fibrin-derived peptide	GHRPLDKKREEAPSLRPAPPPISGGGYR	"SARS-CoV-2,EboV"	16208062	C133H216N44O38	Not Available	Not Available	Not Available	88650-17-3	Not Available	25534190##33844613	No comments found.	"FX-06 is a fibrin-derived synthetic peptide used for treatment of vascular leak syndrome in Ebola virus disease, Phase 2 trials for COVID-19 treatment."	DRAVPc006.png	COVID-19	Peptide	Phase ｊ clinical trial	"Anti-SARS-CoV-2,Anti-EBOV"
DRAVPc005	Sifuvirtide	SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE	HIV	49769437	C201H307N59O71	Not Available	Not Available	Not Available	Not Available	Not Available	23233535##22228771	No comments found.	"Sifuvirtide is a linear 36-amino acid residues anti-HIV peptide, which designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformation."	DRAVPc005.png	HIV Infections	Peptide	Phase ｋ clinical trial	Anti-HIV
DRAVPc004	"Enfuvirtide(Fuzeon, DP178)"	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF	"HIV,SARS-CoV-2"	16130199	C204H301N51O64	DB00109	C2105	19OWO1T3ZE	159519-65-0	CHEMBL525076	33438525##33844613	No comments found.	"Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. By disrupting the HIV-1 molecular machinery during its final stage of fusion with the target cell, enfuvirtide limits the spread of further infection."	DRAVPc004.png	HIV Infections	Peptide	Approved	"Anti-HIV,Anti-SARS-CoV-2"
DRAVPc003	Plitidepsin(Aplidine)	Not available	"HCV,HIV"	3010818	C36H53N7O6	DB05521	C1689	Y76ID234HW	137219-37-5	CHEMBL451930	22180548##22332992	No comments found.	"Plitidepsin is a didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans. It has a role as a marine metabolite, an antineoplastic agent and an anticoronaviral agent."	DRAVPc003.png	Chronic HCV infection	Peptide	Phase ｋ clinical trial	"Anti-HCV,Anti-HIV"
DRAVPc002	Boceprevir	Not Available	"HCV,HIV"	10324367	C27H45N5O5	DB08873	C117292	89BT58KELH	394730-60-0	CHEMBL218394	22975763##22506260	No comments found.	"Boceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Initially approved for use in 2012, it was withdrawn in 2015 because of the availability of more effective and better tolerated all oral regimens of direct acting antiviral agents. Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b."	DRAVPc002.png	Chronic HCV infection	Peptidomimetic	"Approved,  Withdrawn"	"Anti-HCV,Anti-HIV"
DRAVPc062	Bebtelovimab	">Heavy Chain
QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>Light Chain
QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS"	SARS-COV-2	472424854	Not Available	DB16755	C182122	8YL4SYR6CU	2578319-11-4	CHEMBL4802210	33972947	No comments found.	"Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the epitope to which it binds appears infrequently mutated, making it a viable candidate for use in resistant SARS-CoV-2 strains (i.e. variants of concern, VOCs), including the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants. Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients."		COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc001	Brilacidin	Not Available	SARS-CoV-2	25023695	C40H50F6N14O6	DB12997	C169816	I1679X069H	1224095-98-0	CHEMBL2219413	35080027##35695877##33572467	No comments found.	"Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins."	DRAVPc001.png	COVID-19	small molecule mimetic of defensin	Phase ｊ clinical trial	Anti-SARS-CoV-2
DRAVPc044	PUL-042(PAM2CSK4 acetate)	XSKKKK	SARS-CoV-2	165411979	C65H126N10O12S	DB16474	Not Available	L33ZW7BO91	574741-81-4	Not Available	35356002##36569949	"X is cysteine, where the side-chain mercaptan hydrogen on the Cys residue is replaced by 2, 3-di (palmitoyl oxyl) propyl."	Pam2 is a synthetic lipopeptide which acts as an agonist at TLR2 and TLR6. Actions at these receptors suggest that Pam2 has potential antiviral properties.	DRAVPc044.png	COVID-19	Peptide		Anti-SARS-CoV-2
DRAVPc045	Aviptadil	HSDAVFTDNYTRLRKQMAVKKYLNSILN	SARS-CoV-2	16132300	C145H232N40O43S	DB16474	C171932	A67JUW790C	40077-57-4	CHEMBL2106041	34846667##36227034	No comments found.	"Aviptadil is a synthetic form of vasoactive intestinal polypeptide (VIP), with potential anti-cytokine, anti-inflammatory, and immune-regulatory activities. Upon administration, aviptadil mimics endogenous VIP. In the lungs, aviptadil may prevent N-Methyl-D-aspartic acid (NMDA)-induced caspase-3 activation, inhibits the production of certain pro-inflammatory mediators, such as interleukin-6 (IL-6) and tumor-necrosis factor-alpha (TNFa), and may protect the lungs against a cytokine storm and inflammation. As cytokines cause the air sacs of the lungs to fill with water, making the sacs impermeable to oxygen, aviptadil may protect against pulmonary edema, and restores the barrier function at the endothelial/alveolar interface. This may improve blood oxygenation, respiratory distress, and prevent lung injury. VIP is a naturally synthesized peptide hormone that is highly concentrated in the lungs."	DRAVPc045.png	COVID-19	Peptide	Phase ｋ clinical trial	Anti-SARS-CoV-2
DRAVPc046	Solnatide	CGQRETPEGAEAKPWYC	SARS-CoV-2	91864495	Not Available	DB12136	C152387	17ZS80333G	259206-53-6	CHEMBL4297885	35379296	No comments found.	Solnatide has been used in trials studying the treatment of Acute Lung Injury.	DRAVPc046.png	COVID-19 caused Acute Lung Injury	Peptide	Phase ｊ clinical trial	Anti-SARS-CoV-2
DRAVPc047	Metenkefalin	YGGFM	SARS-CoV-2	443363	C27H35N5O7S	DB12668	C91011	9JEZ9OD3AS	58569-55-4	CHEMBL13786	Not Available	No comments found.	"Metenkefalin is a synthetic form of the naturally occurring, endogenous opioid peptide, metenkephalin, and agonist of the zeta- and delta-opioid receptor and, to a lesser extent the mu-opioid receptor, with potential analgesic, neuromodulatory, immunomodulatory, anti-inflammatory, antinociceptive/analgesic, antidepressant, and gastrointestinal (GI) motility modulating activities. It is an investigational endogenous opioid being studied for the treatment of COVID-19. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory therapy for moderate to severe COVID-19."	DRAVPc047.png	COVID-19	Peptide	Phase ｋ clinical trial	Anti-SARS-CoV-2
DRAVPc048	Hepalatide	GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVG	HBV	438788936	Not Available	Not Available	Not Available	8WL68J66B9	Not Available	Not Available	Not Available	No comments found.	Hepalatide is used for the treatment of chronic hepatitis B virus infection.	                 	Chronic HBV infection	Peptide	Phase ｊ clinical trial	
DRAVPc049	Flufirvitide-3(free c-terminal acid)	VEDTKIDLWSYNAELL	Influenza virus	134812039	C87H133N19O29	Not Available	Not Available	QOG7VHU2LU	156953-42-3	Not Available	35853393	No comments found.	Flufirvitide-3 is used for the treatment of influenza virus infection.	DRAVPc049.png	Influenza virus infection	Peptide		
DRAVPc050	Adaptavir(Dapta)	ASTTTNYT	"HIV, HBV"	184644	C35H56N10O15	DB16290	Not Available	J208V4ZMP2	106362-34-9	CHEMBL181276	11530189##16002156	No comments found.	Adaptavir is under clinical for the treatment of HIV infection.	DRAVPc050.png	HIV infection	Peptide	Phase ｊ clinical trial	
DRAVPc051	CSA0001(LL-37 antiviral peptide)	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	SARS-CoV-2	155907172	C205H340N60O53	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	No comments found.	LL-37 is under clinical for the treatment of COVID-19.		COVID-19	Peptide		
DRAVPc052	Angiotensin (1-7)(TXA127)	DRVYIHP	SARS-CoV-2	123805	C41H62N12O11	DB11720	C68962	IJ3FUK8MOF	51833-78-4	CHEMBL3545347	36579082##36453502	No comments found.	"Therapeutic Angiotensin-(1-7) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II."	DRAVPc052.png	COVID-19	Peptide	Phase ｊ clinical trial	
DRAVPc053	Angiotensin II	DRVYIHPF	SARS-CoV-2	172198	C50H71N13O12	DB11842	C173802	M089EFU921	4474-91-3	CHEMBL408403	36584778##36378226	No comments found.	"Angiotensin II is a peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock. As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. It is under investigation in clinical trial for the treatment of COVID-19."	DRAVPc053.png	COVID-19	Peptide	Approved	
DRAVPc054	Compstatin 40(AMY-101)	YICVXQDWGAHRCI	SARS-CoV-2	131634231	C83H117N23O18S2	DB14803	C173801	4Z4DFR9BX7	1427001-89-5	CHEMBL4297260	35977025##32759504	"X is Trp(Me), a methylated form of tryptophan"	"C3 Complement Inhibitor AMY-101 is a compstatin-based inhibitor of human complement component C3, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). Upon administration, C3 complement inhibitor AMY-101 selectively binds to C3 and inhibits C3 activity. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a crucial and central component of the complement system, and the complement system is an integral component of the innate immune response."	DRAVPc054.png	COVID-19	Peptide	Phase ｊ clinical trial	
DRAVPc063	Casirivimab	Not Available		472422356	Not Available	DB15941	C177087	J0FI6WE1QN	2415933-42-3	CHEMBL4650248	32540901##32807860	No comments found.	"Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA."		COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc064	Imdevimab	Not Available		472422363	Not Available	DB15940	C177063	2Z3DQD2JHM	2415933-40-1	CHEMBL4650249	32540904##32540901	No comments found.	"Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA."		COVID-19	Antibody	Approved	Anti-SARS-CoV-2
DRAVPc065	Ombitasvir	Not Available	HCV	54767916	C50H67N7O8	DB09296	C123878 	EQE3I70J3W	1258226-87-7	CHEMBL3127326	"27179128##
24400777##27401997##28497432##
15302943##
25585348##
9305675"	No comments found.	"Ombitasvir (ABT-267) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6. In 2015, it was approved by FDA for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1."	DRAVPc065.png	Hepatitis C Virus (HCV) infection	peptide	"Approved, Investigational"	Anti-HCV
DRAVPc066	Lopinavir	Not Available	HIV-1	92727	C37H48N4O5	DB01601	?C2095	2494G1JF75	192725-17-0	CHEMBL729	9884314##19108994##9835517##30346663##22762019##21953914	No comments found.	"Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection.?Lopinavir is marketed and administered exclusively in combination with?ritonavir?- this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration ""boosts"" lopinavir exposure and improves antiviral activity.Like many other protease inhibitors (e.g.?saquinavir,?nelfinavir), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease."	DRAVPc066.png	human immunodeficiency virus (HIV) infection.	peptidomimetic	Approved	Anti-HIV
DRAVPc067	Nirsevimab	">Heavy_chain QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLEGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>Light_chain DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	RSV	Not available	C6494H10060N1708O2050S46	DB16258	C170224	VRN8S9CW5V	1989556-22-0	wu	"35544094##35235726##
32726528##
26641933##29373476"	No comments found.	"Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1?) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants. Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication."		respiratory syncytial virus (RSV) lower respiratory tract disease	antibody	"Approved, Investigational"	Anti-RSV
DRAVPc068	Grazoprevir	Not Available	HCV	44603531	C38H50N6O9S	DB11575	C166768	8YE81R1X1J	1350514-68-9	CHEMBL2063090	"25585348##
28497432##
22615282##
24900473##
24666106"	No comments found.	"Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy in combination with Elbasvir for genotypes 1a, 1b, and 4 of Hepatitis C."	DRAVPc068.png	hepatitis C virus infections.	Cyclic peptidomimetic	Approved	Anti-HCV
DRAVPc069	Asunaprevir	Not Available	Hepatitis C virus genotype 1b	16076883	C35H46ClN5O9S	DB11586	?C114982	S9X0KRJ00S	630420-16-5	CHEMBL2105735	"25061308?##
22508297##
22256805"	No comments found.	"Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.?It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017."	DRAVPc069.png	hepatitis C genotype 1b	peptide	"Approved, Investigational, Withdrawn"	Anti-HCV
DRAVPc070	Voxilaprevir	Not Available	HCV	89921642	C40H52F4N6O9S	DB12026	C152922	0570F37359	1535212-07-7	CHEMBL4474855	23463199##28564569	No comments found.	"Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).Voxilaprevir has been available since July 2017 in a fixed dose combination product with sofosbuvir and velpatasvir as the commercially available product Vosevi. Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection."	DRAVPc070.png	Hepatitis C infections	Cyclic peptidomimetic	"Approved, Investigational"	Anti-HCV
DRAVPc071	Etesevimab	Not Available	SARS-CoV-2	Not available		DB15897	C173977	N7Q9NLF11I	2423948-94-9			No comments found.	"Etesevimab is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children."		COVID-19	antibody	Investigational	Anti-SARS-CoV-2
DRAVPc072	Tocilizumab	">Tocilizumab light chain:
DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPS
RFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT  >Tocilizumab heavy chain:
QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTY
NPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSSA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPG
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"	SARS-CoV-2	347910344	C6428H9976N1720O2018S42	DB06273	C84217	I031V2H011	375823-41-9	CHEMBL1237022	27599663##25190079##20608753##12669473##32278585	No comments found.	"Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.It was approved by Health Canada on 30 April 2010.11 After being investigated to treat severely ill patients with COVID-19,1,7,8 tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation."		COVID-19	antibody	Approved	Anti-SARS-CoV-2
DRAVPc073	nirmatrelvir	Not Available	SARS-CoV-2	155903259	C23H32F3N5O4	DB16691	?C182119	7R9A5P7H32	2628280-40-8	CHEMBL4802135	33460213##27799534##33098476	No comments found.	"Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531.In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and ritonavir, for the treatment of certain patients with mild-to-moderate COVID-19.Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 and later granted conditional marketing authorization by the European Commission on January 27, 2022."		COVID-19	peptidomimetic	"Approved, Investigational"	Anti-SARS-CoV-2
DRAVPc074	simeprevir	Not Available	HCV	24873435	C38H47N5O7S2	DB06290	C129015	9WS5RD66HZ	923604-59-5	CHEMBL501849	"25585348##
20166108##
26694454##
25206310##
24920913##
18678486"	No comments found.	"Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. Simeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. Administered once daily with food, 150mg simeprevir capsule is used in combination with Sofosbuvir in patients with HCV genotype 1 without cirrhosis ."		HCV	Cyclic peptidomimetic	Approved	Anti-HCV
DRAVPc075	glecaprevir	Not Available	HCV	66828839	C38H46F4N6O9S	DB13879	?C170029	K6BUU8J72P	1365970-03-1	CHEMBL3545363	24282816	No comments found.	Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. Glecaprevir is available as an oral combination therapy with Pibrentasvir under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017.		HCV	Cyclic peptidomimetic	"Approved, Investigational"	Anti-HCV
DRAVPc076	voxilaprevir	Not Available	HCV	89921642	C40H52F4N6O9S	DB12026	C152922	0570F37359	1535212-07-7	CHEMBL4474855	"23463199 ##
28564569"	No comments found.	"Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Voxilaprevir has been available since July 2017 in a fixed dose combination product with sofosbuvir and velpatasvir as the commercially available product Vosevi."		HCV	Cyclic peptidomimetic	"Approved, Investigational"	Anti-HCV
DRAVPc077	daclatasvir	Not Available	HCV	25154714	C40H50N8O6	DB09102	C114981	LI2427F9CI	1009119-64-5	CHEMBL2023898	"27029743##
25585348##
25046163##
24204123##
26486762##
23431163##24521299"	No comments found.	"Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg Sofosbuvir for genotype 1a/b patients with or without cirrhosis as second-line therapy."		HCV	peptidomimetic	"Approved, Investigational"	Anti-HCV
DRAVPc078	sofosbuvir	Not Available	HCV	45375808	C22H29FN3O9P	DB08934	?C101263	WJ6CA3ZU8B	1190307-88-0	CHEMBL1259059	"26426038##
27482432##
9305675##
28248189##
23262999##
26196665##
25585348##
28497432##
15483230##
25659285##
24733478##
24289735
20801890##"	No comments found.	"Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).Since 2014, sofosbuvir has been available as a fixed dose combination product with Ledipasvir (tradename Harvoni) used for the treatment of chronic Hepatitis C. Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without Ribavirin depending on the level of liver damage or cirrhosis Label."		HCV	peptidomimetic	Approved	Anti-HCV
